Plasmacytoma of the uvea in a case of multiple myeloma

Abstract

A case of plasmacytoma in the uvea, both clinically and grossly anatomically mimicking a malignant melanoma, is described in a 63-year-old man who died from multiple myeloma. This is an extremely rare condition in the eye. Only one report of a similar tumour has been found in the literature.

Intraocular plasmacytoma: A case of iris involvement and a review of the literature

“… 14 , 15 The two patients that were treated with systemic chemotherapy alone expired within 6 months of ocular tumor detection from complications associated with multiple myeloma. 4 , 16 For the 5 (29%) cases that presented with SEMP and had reported follow-up, there was no evidence of development of multiple myeloma after mean follow-up of 5 years (range 3–9 years). 6 , 8 , 11 , 12 , 17 For the 8 (47%) patients with multiple myeloma and reported follow-up, 4 (50%) patients died from multiple myeloma-associated complications, 3 (38%) patients had systemic disease improvement with treatment, and our case had systemic disease progression with local ocular tumor regression.…”

“…No evidence of MM. 63 16 M N/A Y Choroid Y N/A Chemotherapy, radiotherapy 1 month Deceased from complications of MM. 67 4 M N/A Y Iris Y N/A Chemotherapy 6 months Deceased from complications of MM.…”

“…Both patients died of multiple myeloma-associated complications shortly after treatment with one demonstrating ocular tumor recurrence after treatment and the other having external beam radiation as a palliative but not curative treatment for management of secondary glaucoma. 7 , 13 The remaining patients were treated with intravitreal and systemic chemotherapy (n = 2, 12%), 14 , 15 systemic chemotherapy alone (n = 2, 12%), 4 , 16 or primary enucleation for secondary glaucoma (n = 2, 12%). 17 , 18 The two patients that were treated with intravitreal and systemic chemotherapy demonstrated ocular tumor regression.…”

“… 6 , 8 , 11 , 12 , 17 For the 8 (47%) patients with multiple myeloma and reported follow-up, 4 (50%) patients died from multiple myeloma-associated complications, 3 (38%) patients had systemic disease improvement with treatment, and our case had systemic disease progression with local ocular tumor regression. 4 , 7 , 9 , 10 , 13 , 15 , 16 …”